Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Deals

Pair of Roche deals add allogeneic cell therapies, first-in-class fibrosis molecule

Deals provide substantial cash runway extensions for Poseida, Kiniksa

August 3, 2022 10:23 PM UTC

Roche spent more than $200 million in upfront payments to expand its interest in allogeneic cell therapies for cancer and add a first-in-class molecule for fibrosis.

On Wednesday, Poseida Therapeutics Inc. (NASDAQ:PSTX) granted Roche (SIX:ROG; OTCQX:RHHBY) exclusive rights and options to multiple allogeneic CAR T therapy programs, including P-BCMA-ALLO1, which is a BCMA-targeted CAR T therapy in Phase I testing to treat multiple myeloma; and P-CD19CD20-ALLO1, a dual-targeting CAR T against CD19 and CD20 that is expected to enter the clinic next year. The partners will also jointly discover and develop next-generation allogeneic CAR T therapies that Roche would have an option to license...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article